Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Antonio Gonzalez-MartinChristian Kurzeder

Abstract

In platinum-resistant ovarian cancer, adding pertuzumab to gemcitabine improved progression-free survival in the subgroup with low tumor HER3 messenger RNA expression. The 2-part PENELOPE trial (NCT01684878) is prospectively investigating pertuzumab plus chemotherapy in this population. Part 1 evaluated pertuzumab plus either topotecan or paclitaxel. Patients with platinum-refractory or platinum-resistant recurrent ovarian, primary peritoneal, or fallopian tube cancer and low HER3 messenger RNA expression (concentration ratio ≤2.81 by central quantitative reverse transcriptase-polymerase chain reaction testing on Cobas z480) received intravenous pertuzumab (840 mg loading dose then 420 mg every 3 weeks) with the investigator's choice of topotecan (1.25 mg/m2 days 1-5 every 3 weeks) or weekly paclitaxel (80 mg/m2) until disease progression or unacceptable toxicity. The primary objective was to assess safety and tolerability. Fifty patients were treated in part 1 (22 topotecan; 28 paclitaxel). In both cohorts, disease progression was the most common primary reason for discontinuing pertuzumab, and the most common all-grade adverse events (AEs) were fatigue/asthenia, anemia, and diarrhea. The most common grade ≥3 AEs were anemia (...Continue Reading

References

Aug 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S GordonBeth Y Karlan
Aug 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Berno TannerJan Georg Hengstler
Jan 24, 2007·Molecular Cancer Therapeutics·Peter MullenSimon P Langdon
Jun 19, 2009·Nature Reviews. Cancer·José Baselga, Sandra M Swain
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharmila MakhijaUrsula Matulonis
Dec 17, 2009·Expert Opinion on Biological Therapy·Katrin Kristjansdottir, Don Dizon
Aug 11, 2010·Expert Opinion on Biological Therapy·Lukas C Amler
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Jul 12, 2012·Breast Cancer Research and Treatment·Aaron M DruckerMario E Lacouture
Mar 13, 2014·Gynecologic Oncology·Alison DavisMichael Friedlander
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard
Mar 25, 2014·Cancer Treatment Reviews·Min YanRazelle Kurzrock
Feb 19, 2015·The New England Journal of Medicine·Sandra M SwainUNKNOWN CLEOPATRA Study Group

❮ Previous
Next ❯

Citations

Aug 20, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Domenica LorussoUNKNOWN PENELOPE trial investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.